120 related articles for article (PubMed ID: 32918702)
1. Effect of canakinumab on clinical and biochemical parameters in acute gouty arthritis: a meta-analysis.
Jena M; Tripathy A; Mishra A; Maiti R
Inflammopharmacology; 2021 Feb; 29(1):35-47. PubMed ID: 32918702
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis.
Chakraborty A; Van LM; Skerjanec A; Floch D; Klein UR; Krammer G; Sunkara G; Howard D
J Clin Pharmacol; 2013 Dec; 53(12):1240-51. PubMed ID: 24122883
[TBL] [Abstract][Full Text] [Related]
3. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study.
Schlesinger N; De Meulemeester M; Pikhlak A; Yücel AE; Richard D; Murphy V; Arulmani U; Sallstig P; So A
Arthritis Res Ther; 2011 Mar; 13(2):R53. PubMed ID: 21439048
[TBL] [Abstract][Full Text] [Related]
4. Canakinumab for the Patient With Difficult-to-Treat Gouty Arthritis: Review of the Clinical Evidence.
Bardin T
Joint Bone Spine; 2015 Oct; 82 Suppl 1():eS9-16. PubMed ID: 26717801
[TBL] [Abstract][Full Text] [Related]
5. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.
So A; De Meulemeester M; Pikhlak A; Yücel AE; Richard D; Murphy V; Arulmani U; Sallstig P; Schlesinger N
Arthritis Rheum; 2010 Oct; 62(10):3064-76. PubMed ID: 20533546
[TBL] [Abstract][Full Text] [Related]
6. Canakinumab: a guide to its use in acute gouty arthritis flares.
Lyseng-Williamson KA
BioDrugs; 2013 Aug; 27(4):401-6. PubMed ID: 23649936
[TBL] [Abstract][Full Text] [Related]
7. The Way Forward: Practical Clinical Considerations for the Use of Canakinumab in Patients With Difficult-to-Treat Gouty Arthritis.
Bardin T; van de Laar MA
Joint Bone Spine; 2015 Oct; 82 Suppl 1():eS30-2. PubMed ID: 26717800
[TBL] [Abstract][Full Text] [Related]
8. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.
Schlesinger N; Alten RE; Bardin T; Schumacher HR; Bloch M; Gimona A; Krammer G; Murphy V; Richard D; So AK
Ann Rheum Dis; 2012 Nov; 71(11):1839-48. PubMed ID: 22586173
[TBL] [Abstract][Full Text] [Related]
9. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.
Schlesinger N; Mysler E; Lin HY; De Meulemeester M; Rovensky J; Arulmani U; Balfour A; Krammer G; Sallstig P; So A
Ann Rheum Dis; 2011 Jul; 70(7):1264-71. PubMed ID: 21540198
[TBL] [Abstract][Full Text] [Related]
10. Difficult-to-treat gouty arthritis: a disease warranting better management.
Schlesinger N
Drugs; 2011 Jul; 71(11):1413-39. PubMed ID: 21812506
[TBL] [Abstract][Full Text] [Related]
11. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
Ridker PM; MacFadyen JG; Everett BM; Libby P; Thuren T; Glynn RJ;
Lancet; 2018 Jan; 391(10118):319-328. PubMed ID: 29146124
[TBL] [Abstract][Full Text] [Related]
12. Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy.
Schlesinger N
Semin Arthritis Rheum; 2012 Oct; 42(2):155-65. PubMed ID: 22542277
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis-related health outcomes measures.
Hirsch JD; Gnanasakthy A; Lale R; Choi K; Sarkin AJ
Int J Clin Pract; 2014 Dec; 68(12):1503-7. PubMed ID: 25298264
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Xixiancao (Herba Siegesbeckiae Orientalis) on interactions between nuclear factor kappa-B and inflammatory cytokines in inflammatory reactions of rat synovial cells induced by sodium urate.
Wang Z; Fan X; Xu Y; Chen K; Yu X; Sun G
J Tradit Chin Med; 2020 Oct; 40(5):774-781. PubMed ID: 33000578
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis.
Cronstein BN; Sunkureddi P
J Clin Rheumatol; 2013 Jan; 19(1):19-29. PubMed ID: 23319019
[TBL] [Abstract][Full Text] [Related]
16. [Canakinumab: a promising treatment in rheumatology].
Fabreguet I; So A
Rev Med Suisse; 2012 Jan; 8(323):57-60. PubMed ID: 22303742
[TBL] [Abstract][Full Text] [Related]
17. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
Ridker PM; MacFadyen JG; Thuren T; Everett BM; Libby P; Glynn RJ;
Lancet; 2017 Oct; 390(10105):1833-1842. PubMed ID: 28855077
[TBL] [Abstract][Full Text] [Related]
18. Effects of Interleukin-1β Inhibition on Incident Anemia: Exploratory Analyses From a Randomized Trial.
Vallurupalli M; MacFadyen JG; Glynn RJ; Thuren T; Libby P; Berliner N; Ridker PM
Ann Intern Med; 2020 Apr; 172(8):523-532. PubMed ID: 32203978
[TBL] [Abstract][Full Text] [Related]
19. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study.
Koné-Paut I; Lachmann HJ; Kuemmerle-Deschner JB; Hachulla E; Leslie KS; Mouy R; Ferreira A; Lheritier K; Patel N; Preiss R; Hawkins PN;
Arthritis Res Ther; 2011; 13(6):R202. PubMed ID: 22152723
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review.
Schlesinger N; Pillinger MH; Simon LS; Lipsky PE
Arthritis Res Ther; 2023 Jul; 25(1):128. PubMed ID: 37491293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
